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Summary 
Background: Glaucoma is a highly prevalent eye disease
related to optic nerve lesions and visual field defects. Primary
Open-Angle Glaucoma (POAG) is a type of glaucoma that
occurs frequently with unknown etiology. In this study, we
investigated the serum levels of selenium, selenoprotein P1,
glutathione, hemolysate glutathione peroxidase1 (GPx1)
activity and aqueous humour selenium in POAG patients.
Methods: Ninety sex- and age-matched subjects (POAG
patients; n=45 and, controls; n=45) with the controlled
confounders (smoking, hypertension and alcohol beverages)
were recruited on clinical histories and exams. The serum
and aqueous humour selenium levels were measured using
GFAAS technique. The serum selenoprotein P1 level was
assayed with the ELISA method. The hemolysate GPx1 activ-
ity and serum reduced glutathione level were also measured
using known colorimetric techniques. 
Results: The serum selenium (P=0.01) and selenoprotein
P1 (P<0.001) levels were significantly high in POAG
patients. Furthermore, the aqueous humour selenium level
was significantly high among patients as compared to con-
trols (64.68±13.07 vs. 58.36±13.76 ng/mL, P=0.02).
The results did not show a significant difference (P=0.36) in
the hemolysate GPx1 activity between the groups. The cut-
off points for intraocular pressure (IOP) and serum seleno-
protein P1 parameters were estimated to be 39 mmHg (sen-
sitivity 97.5%; 1-specificity 6.5%) and 188 mg/mL (sensitivity
93.5%; 1-specificity 14%), respectively. 
Kratak sadr`aj
Uvod: Glaukom je veoma ~esto oboljenje oka koje je po -
vezano sa lezijama na o~nom `ivcu i o{te}enjima vidnog
polja. Primarni glaukom otvorenog ugla (PGOU) tip je
glaukoma sa ~esto nepoznatom etiologijom. U ovoj studiji
ispitivani su serumski nivoi selena, selenoproteina P1, gluta-
tiona, aktivnost hemolizata glutation-peroksidaze1 (GPx1) i
selen u o~noj vodici kod pacijenata sa PGOU. 
Metode: Na osnovu klini~ke istorije i pregleda, obuhva}eno
je 90 subjekata odgovaraju}eg pola i starosne dobi (pacijen-
ti sa PGOU; n=45 i kontrolni subjekti; n=45) sa kontroli -
sanim varijablama (pu{enje, hipertenzija i alkoholna pi}a).
Ni voi selena u serumu i o~noj vodici izmereni su pomo}u
tehnike GFAAS. Nivo selenoproteina P1 u serumu odre|en
je me todom ELISA. Aktivnost hemolizata GPx1 i nivo redu -
kovanog glutationa u serumu tako|e su mereni poznatim
kolorimetrij skim tehnikama. 
Rezultati: Serumski nivoi selena (P=0,01) i selenoproteina
P1 (P=0,001) bili su zna~ajno vi{i kod pacijenata sa PGOU.
Uz to, nivo selena u o~noj vodici bio je zna~ajno vi{i kod paci-
jenata nego u kontrolnoj grupi (64,68±13,07 prema 58,36
±13,76 ng/mL, P=0,02). Rezultati nisu otkrili zna~ajnu raz-
liku (P=0,36) u aktivnosti hemolizata GPx1 izme|u grupa.
Odre|ene su cutoff vrednosti za intraokularni pritisak (IOP) i
parametre serumskog selenoproteina P1: 39 mmHg (ose -
tljivost 97,5%; 1-specifi~nost 6,5%), odnosno 188 mg/mL
(osetljivost 93,5%; 1-specifi~nost 14%). 
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Introduction
Glaucoma is an eye disease related to the optic
nerve damage and visual field loss (1). It is the sec-
ond leading cause of blindness after cataract. Based
on the trabecular meshwork (TM) obstruction, glau-
coma can clinically be observed in two forms, Open-
Angle Glaucoma (POAG) and Primary Closed-angle
glaucoma (PACG). Primary Open-Angle Glau coma
(POAG) is a type that frequently occurs in the United
States; however, a shift is considered in the demo-
graphic and geographic characteristics of the patients
(2). The high prevalence of glaucoma is also report-
ed in Asian countries (3). In PACG, the iris obstructs
the trabecular meshwork in the angle of the eyes,
whereas in POAG, the trabecular meshwork seems to
be open and unobstructed by the iris (4). Although
the POAG etiology is unknown, ganglion cell death is
proposed to be due to high eye pressure, decreased
blood flow to the optic nerve head, inflammatory
events, and increased nitric oxide and glutamate lev-
els (5, 6). In addition to the above factors (7), other
agents such as high selenium in bodily fluids, molec-
ular genetics and some demographic parameters
have also been suggested to be involved in glaucoma,
but so far the evidence is inconclusive (8–10). 
Selenium is present in body fluids (11) and is
known as a functional trace element in the human
lens (12). Some studies have reported the association
between serum selenium level and glaucoma (13) and
have shown that selenium overload within aqueous
humour may cause a decrease in trabecular meshwork
cell adhesion and activation of apoptotic signaling
pathways (14, 15). Based on these reports, we evalu-
ated the levels of selenium, selenoprotein P1 and
some antioxidant parameters to test the hypothesis
which suggests POAG may be related to a high sele-
nium level.
Methods
Subjects
The sex and age-matched subjects were recruit-
ed upon clinical exams. The POAG patients (n=45)
were excluded for secondary glaucoma, congenital
glaucoma and PACG and were candidates for tra-
beculectomy or phacoemulsification. Controls (n=45)
had clinically normal optic nerves and intraocular
pressure which did not contribute to POAG risk. The
study was approved by the university ethics commit-
tee and informed consent was ob tained from all sub-
jects.
Samples
Two blood specimens (each 5 mL) were collect-
ed in the blood tubes. The clotted and EDTA blood
tubes were centrifuged at 3000 g (15 min) and the
serum and plasma were separated and stored at
–80 ˚C. The remaining red pellets were washed three
times with normal saline (NaCl, 0.9%) and were dilut-
ed with distillated water for preparation of erythrocyte
hemolysate (1: 1 V/V).   
Serum and aqueous humour selenium levels
The serum and aqueous humour selenium values
were measured using Graphite Furnace atomic absorp-
tion spectrometry (GFAAS). Five mL HNO3 (16 mol/L)
was added to 2.5 mL serum and then slowly heated up
to 140 °C (20 min). The above stage was repeated with
an acidic solution containing 2.5 mL H2SO4 (18
mol/L) and 1 mL HClO4 (11.6 mol/L). Then, 5 mL
HCl (5 mol/L) was added after cooling and 10 mL from
it was injected into a Parker Elmer ato mic spectrometer
(Mercury Hydride system). The aqueous humour sam-
ples were directly injected into the system.
Selenoprotein P1
The serum selenoprotein P1 concentration was
measured with the ELISA method (Antibodies Online,
Cusabio Biotech Co). According to the protocol, 5 mL
sera were diluted and incubated with reagents.  Then,
the serum selenoprotein P1 concentration was calcu-
lated on the standard curve (Boot strapping, 100).
Glutathione (GSH)
The serum sample was mixed with the precipi-
tating reagent (metaphosphoric acid (100 g/L) and
phosphate buffer (0.3 mol/L, pH 7.5)) and cen-
trifuged at 2000 g (2 min).  0.2 mL phosphate buffer
(0.3 mol/L, pH 7.5) was mixed with 200 mL super-
natant and the sample absorption (A) was identified
at 412 nm (Beutler method). 
Glutathione concentration (nmol/mL) = (A/mo -
lar extinction coefficient (GSH))×Dilution coefficient 
Conclusions: The results also showed the selenium and
selenoprotein P1 levels relate to intraocular pressure. We sug-
gested serum selenoprotein P1 and intraocular pressure are
more sensitive factors for the primary screening of POAG. 
Keywords: selenium, selenoprotein P1, glutathione per -
oxidase 1, glutathione, glaucoma
Zaklju~ak: Rezultati su tako|e pokazali da su nivoi selena i se -
lenoproteina P1 povezani sa intraokularnim pritiskom. Uka zali
smo na to da su selenoprotein P1 u serumu i intra okularni pri-
tisak osetljiviji faktori za primarni skrining za PGOU. 
Klju~ne re~i: selen, selenoprotein P1, glutation peroksi-
daza 1, glutation, glaukom
Hemolysate GPx1 activity
The hemolysate GPx1 enzyme was coupled to
glutathione reductase (GR) and its activity was nor -
malized with the hemolysate hemoglobin (Hb) con-
centration (Zist-Shimi Co). According to the method,
20 mL of the hemolysate was added to 400 mL of
reactive reagent (8 mL phosphate buffer (100
mmol/L, pH 7.4), 4 mL GR (5000 U/L), 2 mL GSH
(2.5 mmol/L) and 2 mL NADPH (2.5 mmol/L)).
Then, 20 mL TBHP (25 mmol/L) was added to the
previous solution and the absorbance changes (DOD)
were calculated after an incubation period (3 min)
(16).
GPx1 activity (U/g Hb) = ((DOD × dilution co -
effi cient)/molar extinction coefficient (NADPH))/10
× Hb (g/dL)
Total Antioxidant Capacity (TAC)
According to the method, ABTS (2, 2’-azino-di
(3-ethylbenzthiazoline-6-sulfononate) is converted to
ABTS°+ (oxidized ABTS, green) by H2O2. Then, linear
decolorization follows in the presence of serum antiox-
idants. 200 mL reagent 1 (Buffer acetate 0.4 mol/L,
pH 5.8) was mixed with the serum sample (5 mL) and
then its absorbance (660 nm; OD1) was taken as sam-
ple blank. Afterwards, reagent 2 (ABTS°+, buffer
acetate 30 mmol/L, pH 3.6) was added to the previ-
ous mixture and second absor bance (OD2) was taken
after an incubation period (5 min). The results were
reported on the basis of Trolox calibration.
Statistics
Data was analyzed using a statistical software
package (SPSS 18.0, Chicago). The parameters were
evaluated using Student-t and Chi square tests
between control and patient subjects. ROC curve was
also used to identify the cutoff values. Linear regres-
sion analyses were performed and tested between
some parameters. P value less than 0.05 was consid-
ered to be significant. 
Results
The age (P=0.2) and sex (P=0.18) parameters
and some confounders such as systolic blood pressure
(P=0.76), diastolic blood pressure (P=0.59) and
smoking (P=0.82) showed no significant differences
between control and patient subjects. However, signi -
ficant differences were observed in intraocular pres -
sure (IOP) and central corneal thickness (P<0.0001)
(Table I).
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Table I Characteristics of the study population.
Table II Biochemical parameters.
Parameter Control(n=45)
Patient
(n=45) P–Value
Sex (male/female) 26/19 32/13 0.18
Age (years) 67.91±8.05 70.04±7.71 0.20
Body Mass Index (kg/m2) 25.27±4.11 25.31±3.96 0.95
Systolic Blood Pressure (mmHg) 128.00±14.55 128.89±13.35 0.76
Diastolic Blood Pressure (mmHg) 77.32±7.80 78.22±7.76 0.59
Smoking (yes/no) 11/34 10/35 0.82
Intraocular pressure (mmHg) 14.40±2.71 24.85±5.67 <0.0001
Central corneal thickness (microns) 247.50±172.09 427.60±233.08 <0.0001
Parameter Control(n=45)
Patient
(n=45) P-Value
Aqueous humour total antioxidant capacity
(mmol/L Trolox equivalent) 277.30±80.60 281.51±112.22 0.84
Aqueous humour selenium (ng/mL) 58.36±13.76 64.68±13.07 0.02
Serum selenium (ng/mL) 213.57±48.70 237.71±43.49 0.01
Serum selenoprotein P1 (mg/mL) 13.90±10.47 46.68±34.38 <0.001
Serum glutathione (nmol/mL) 3.78±1.49 4.43±1.46 0.045
Hemolysate glutathione peroxidase1 (U/g Hb) 81.58±25.39 76.37±29.28 0.36
Table II shows that the selenium level increases
significantly in the aqueous humour of POAG patients
(P=0.02). Furthermore, the serum selenium
(P=0.01) and selenoprotein P1 (P<0.001) levels,
similar to the aqueous humour selenium, increased
significantly among patients. In contrast, the results
did not show significant differences for the gluta -
thione peroxidase1 (GPx1) activity (P=0.36) and the
total antioxidant capacity (TAC) (P=0.84). The serum
glutathione concentration was slightly in creased in
patients (P=0.045) (Table II).
The results also showed that aqueous humour
selenium had significant linear correlations with the
serum selenium (R2= 0.81, P=0.0001) and intraoc-
ular pressure (R2= 0.75, P =0.045) (Figure 1 A and
B). Based on the ROC curve (Figure 2), we estimated
the selenium (P=0.00; Area 0.744, CI 0.633–
0.855), selenoprotein P1 (P=0.00; Area 0.879, CI
0.797–0.961) and intraocular pressure (P=0.00;
Area 0.989, CI 0.975–1.003) cutoff points and
found that the serum selenoprotein P1 and intraocu-
lar pressure have higher quality characteristics for the
primary screening of POAG. The intraocular pressure
(IOP) and selenoprotein P1 (SEP-P1) cutoff points
were 39 mmHg (sensitivity 97.5%; 1-specificity 6.5%)
and 188 mg/mL (sensitivity 93.5%; 1-spe ci ficity 14%),
respectively. 
Discussion
In this study, the levels of selenium, selenopro-
tein P1, glutathione and GPx1 activity were evaluated
on the basis of a long-term selenium supplementation
study (Nutritional Prevention of Cancer; NPC) that
showed a potential association between selenium and
incidence of glaucoma. In agreement with the NPC
results, our findings revealed that the body’s selenium
level may be one of the causal factors in the develop-
ment of POAG. Some authors, however, did not find
significant associations between selenium and glau-
coma, but they suggested a higher risk for incidence
of glaucoma as selenium level elevates in the aque-
ous humour (17).
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Figure 1 Linear correlation (A) between aqueous humour
selenium and serum selenium, (B) between aqueous humour
selenium and intraocular pressure.
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Figure 2 ROC curve. Intraocular pressure (IOP), serum
selenoprotein P1 (SEP-P1) and selenium (Se) cutoff points
are estimated on clinical sensitivity and 1-specificity (false
positive).
In spite of laboratorial and biological variations,
the results showed an association between POAG and
body’s selenium. The study also revealed a significant
association between POAG and the serum selenopro-
tein P1 level, so that the ROC curve showed that it
may be a more sensitive factor than the serum and
aqueous humour selenium levels. These results point-
ed out that the continuous diffusion of serum seleni-
um into aqueous humour leads to selenium overload
within the MT cells. The increase of cellular selenium
higher than the normal range could change the oxi-
dant balance within the MT cells and may trigger the
apoptotic signals (14). Coneley et al. showed that the
selenium overload within TM cells may affect outflow
resistance, routine phagocytic function and extra -
cellular matrix turnover (18). The oxidant balance is
inversely related to the antioxidant enzyme activities
because some oxidant and antioxidant substances are
known as the enzyme substrates or products. Thus,
cellular involvement of selenium without the consider-
ation of selenoenzymes may describe the TAC results
between control and patient subjects. 
Despite the increase in the body’s selenium con-
centration, the GPx1 activity was not high in POAG
patients. In agreement with other studies (19, 20),
which showed maximum GPx1 activity occurrs with
selenium values higher than 100 ng/mL, we found
that the serum selenium concentrations were higher
than 213 ng/mL. 
The results also showed that the intraocular
pres sure higher than 39 mmHg and serum seleno-
protein P1 levels higher than 188 mg/mL can be con-
sidered as cutoff points in the primary screening of
POAG; however, these results must be confirmed in
other studies. 
Conclusion
We found the aqueous humour selenium level
is correlated to the serum selenium concentration.
The intraocular hypertension also had a correlation
with the selenium and selenoprotein P1 levels, so that
the serum selenoprotein P1 level and intraocular
hypertension are suggested as more sensitive factors
for the primary screening of POAG.
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